// App-Quantinova.ai

: Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

Researchers

Presenter

  • Alice McDonald

Principal Investigators

  • Scott Daigle

  • Franck Morschhauser

  • Gilles Salles

  • Vincent Ribrag

  • Pamela McKay

  • Herve Tilly

  • Anna Schmitt

  • Connie Lee Batlevi

  • Christophe Fruchart

  • Peter Johnson

  • Michael Dickinson

  • Stephen Opat

  • Wojciech Jurczak

  • Guillaume Cartron

  • Thierry Lamy

  • Pier Luigi Zinzani

  • Sarit Assouline

  • John Radford

  • John G. Gribben

  • Corinne Haioun

  • Aristeidis Chaidos

  • Steven Le Gouill

  • Alicia Clawson

  • John Larus

  • Stephen J Blakemore

Medical Centers

  • Epizyme, Cambridge, MA

  • Centre Hospitalier Universitaire, Ottignies, France

  • Department of Pathology and Hematology, Hospices Civils de Lyon, University Lyon 1, Lyon, France

  • Gustave Roussy, Villejuif, France

  • Department of Haematology,Beatson West of Scotland Cancer Centre,Glasgow,United Kingdom

  • Service d'hématologie, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen, France

  • Institut Bergonie, Bordeaux, France

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Centre Francois Baclesse, Caen, France

  • Southampton General Hospital, Southampton, United Kingdom

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Deakin University, Melbourne, Australia

  • UJCM, Krakow, Poland

  • CHU de Montpellier, Montpellier, France

  • CHU Rennes, Rennes, France

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Jewish General Hospital, Montreal, QC, Canada

  • Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

  • Guy's Hospital, London, United Kingdom

  • Hôpital Henri Mondor, Créteil, France,

  • Department of Haematology, Hammersmith Hospital, Imperial Healthcare NHS Trust, London, United Kingdom

  • Service d'hématologie clinique du CHU de Nantes, Nantes, France

Locations

  • United States

  • France

  • United Kingdom

  • Australia

  • Poland

  • Italy

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Circulating DNA

Drug/Treatment

  • Tazemetostat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01897571

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved